Determining the Lipid Lowering Effect of Fenugreek Seed Tea

Launched by QUEEN'S UNIVERSITY, BELFAST · May 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of fenugreek seed tea on lowering fat levels in the blood, specifically in patients with high cholesterol or triglycerides, but who do not have diabetes. Over eight weeks, participants will drink fenugreek tea twice a day and attend three visits at the research center. During these visits, researchers will collect information like weight, blood pressure, and blood samples to see how the tea affects cholesterol levels compared to a control group that will drink regular black tea.

To participate, individuals need to be between 18 and 70 years old and have high triglyceride levels but should not be taking any cholesterol-lowering medications or should have been on stable medication for the last six months. Participants should also be willing to keep their usual diet the same during the study. However, those with diabetes, certain other health conditions, or who are pregnant cannot join. This study aims to find out if fenugreek tea can be a helpful option for managing high cholesterol, and it may also provide insights into new ways to monitor this condition through blood tests.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Both male and female patients aged between 18-70 years old
• • Patients with hyperlipidaemia (plasma triglyceride level between 1.7 - 4.5mmol/l) not on any lipid-lowering treatment or on a stable lipid-lowering treatment (last six months) but still have confirmation of high triglycerides within the range required for study
• • Willing not to change any dietary behaviours, with the exception of participating in the intervention, over the course of the study
• • Participants can be recruited onto the study if they are involved in other research studies, but this will depend on the study type and the decision will be made by the Chief Investigator and/or Principal Investigator.
• Exclusion Criteria:
• • Patients with type 1 or type 2 diabetes, asthma, allergic reactions, respiratory, kidney, and neurological diseases, psychiatric disorders or pre-existing CVD
• • Living in a residential or nursing care home
• • Taking high dose nutritional supplements above the dietary reference values
• • Consumption of alcohol above current recommended levels (14 units per week), pregnancy or lactation
• • Inability to provide informed consent
• • Any other problem which would prevent adherence to fenugreek intervention